Targeted-pig trial on safety and immunogenicity of serum-derived extracellular vesicles enriched fractions obtained from Porcine Respiratory and Reproductive virus infections

Thumbnail
View/Open
Issue date
2018
Author
Montaner Tarbes, Sergio Roberto
Novell, Elena
Tarancón, Vicens
Borrás, Francesc E.
Montoya, Maria
Fraile Sauce, Lorenzo José
del Portillo, Hernando A.
Suggested citation
Montaner Tarbes, Sergio Roberto; Novell, Elena; Tarancón, Vicens; Borrás, Francesc E.; Montoya, Maria; Fraile Sauce, Lorenzo José; del Portillo, Hernando A.; . (2018) . Targeted-pig trial on safety and immunogenicity of serum-derived extracellular vesicles enriched fractions obtained from Porcine Respiratory and Reproductive virus infections. Scientific Reports, 2018, vol.8, núm.17487, p 1-10. https://doi.org/10.1038/s41598-018-36141-5.
Impact

Google Scholar logo  Google Scholar
Share
Export to Mendeley
Metadata
Show full item record
Abstract
The Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is the etiological agent of one of the most important swine diseases with a significant economic burden worldwide. Unfortunately, available vaccines are partially effective highlighting the need of novel approaches. Previously, antigenic
viral proteins were described in serum-derived extracellular vesicles (EVs) from pigs previously infected with PRRSV. Here, a targeted-pig trial was designed to determine the safety and immunogenicity of such extracellular vesicles enriched fractions. Our results showed that immunizations with EV-enriched fractions from convalescence animals in combination with montanide is safe and free of virus as immunizations with up-to two milligrams of EV-enriched fractions did not induce clinical symptoms, adverse effects and detectable viral replication. In addition, this vaccine formulation was able to elicit specific humoral IgG immune response in vaccinated animals, albeit variably. Noticeably, sera from vaccinated animals was diagnosed negative when tested for PRRSV using a commercial ELISA test; thus, indicating that this new approach differentiates vaccinated from infected animals. Lastly, after priming animals with EV-enriched fractions from sera of convalescence animals and boosting them with synthetic viral peptides identified by mass spectrometry, a distinctive high and specific IFN-γ response was elicited. Altogether, our data strongly suggest the use of serum EV-enriched fractions as a novel vaccine strategy against PRRSV.
URI
http://hdl.handle.net/10459.1/65652
DOI
https://doi.org/10.1038/s41598-018-36141-5
Is part of
Scientific Reports, 2018, vol.8, núm.17487, p 1-10
Collections

The following license files are associated with this item:

cc-by (c) Montaner et al., 2018
Except where otherwise noted, this item's license is described as cc-by (c) Montaner et al., 2018